Celgene Corporation (CELG) Shares Sold by Greystone Managed Investments Inc.
Greystone Managed Investments Inc. lowered its position in Celgene Corporation (NASDAQ:CELG) by 2.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 60,187 shares of the biopharmaceutical company’s stock after selling 1,808 shares during the quarter. Greystone Managed Investments Inc.’s holdings in Celgene Corporation were worth $7,816,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Celgene Corporation in the first quarter valued at $118,000. Oakworth Capital Inc. boosted its holdings in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 412 shares during the last quarter. Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation during the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Celgene Corporation by 47.5% during the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 380 shares in the last quarter. Finally, WealthTrust Arizona LLC lifted its stake in shares of Celgene Corporation by 5.2% during the second quarter. WealthTrust Arizona LLC now owns 1,276 shares of the biopharmaceutical company’s stock worth $166,000 after purchasing an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 79.43% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/09/15/celgene-corporation-celg-shares-sold-by-greystone-managed-investments-inc.html.
Celgene Corporation (NASDAQ:CELG) opened at 140.55 on Friday. The stock’s 50 day moving average price is $134.74 and its 200 day moving average price is $127.31. The company has a market capitalization of $109.96 billion, a price-to-earnings ratio of 43.53 and a beta of 1.89. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $142.64.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.44 earnings per share. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
In other Celgene Corporation news, Director Gilla Kaplan sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the completion of the transaction, the director now owns 76,301 shares in the company, valued at $10,264,010.52. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 267,476 shares of company stock valued at $35,812,841. Corporate insiders own 0.95% of the company’s stock.
A number of research analysts have commented on the company. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $96.93 to $131.70 in a research note on Friday, June 30th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research note on Thursday, August 10th. Royal Bank Of Canada assumed coverage on Celgene Corporation in a research note on Thursday. They set a “top pick” rating on the stock. Robert W. Baird restated an “outperform” rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Monday, May 22nd. Finally, SunTrust Banks, Inc. set a $150.00 price objective on Celgene Corporation and gave the stock a “buy” rating in a research note on Thursday, July 6th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $147.31.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.